Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension

Pacific Pharmaceuticals

Status and phase

Unknown

Phase 4

Conditions

Essential Hypertension

Treatments

Drug: Ramipril

Study type

Interventional

Funder types

Industry

Identifiers

NCT00366119

RMN-P01

Details and patient eligibility

About

The purpose of this study is to assess which drug is more effective of Ramiprin®(ramipril) and Tritace®(ramipril) in the Treatment of Essential Hypertension

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

mild and moderate essential hypertension (90mmHg≤DBP≤110mmHg)

Exclusion criteria

180mmHg≤SBP
If differences greater than 20mmHg for SBP and 10mmHg for DBP between both arms are present on 3 consecutive readings
If differences greater than 20mmHg for SBP and 10mmHg for DBP are present on 3 consecutive readings
impaired hepatic function
imapaired renal function
angioedema
aortic valvular stenosis or obstrcutive ejection disorder
primary hyperaldosteronism
renal transplantation, bilateral renal artery stenosis or unilateral stenosis in a single kidney, hemodialysis
severe respiratory disease
congestive heart failure( New York Association functional class Ⅲ or Ⅳ)
malignant hypertension
labile angina pectoris or myocardial infarction in the last 3 months before study entry